These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

189 related items for PubMed ID: 33444606

  • 1. Elafibranor improves diet-induced nonalcoholic steatohepatitis associated with heart failure with preserved ejection fraction in Golden Syrian hamsters.
    Briand F, Maupoint J, Brousseau E, Breyner N, Bouchet M, Costard C, Leste-Lasserre T, Petitjean M, Chen L, Chabrat A, Richard V, Burcelin R, Dubroca C, Sulpice T.
    Metabolism; 2021 Apr; 117():154707. PubMed ID: 33444606
    [Abstract] [Full Text] [Related]

  • 2. Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis.
    Tølbøl KS, Kristiansen MN, Hansen HH, Veidal SS, Rigbolt KT, Gillum MP, Jelsing J, Vrang N, Feigh M.
    World J Gastroenterol; 2018 Jan 14; 24(2):179-194. PubMed ID: 29375204
    [Abstract] [Full Text] [Related]

  • 3. Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening.
    Ratziu V, Harrison SA, Francque S, Bedossa P, Lehert P, Serfaty L, Romero-Gomez M, Boursier J, Abdelmalek M, Caldwell S, Drenth J, Anstee QM, Hum D, Hanf R, Roudot A, Megnien S, Staels B, Sanyal A, GOLDEN-505 Investigator Study Group.
    Gastroenterology; 2016 May 14; 150(5):1147-1159.e5. PubMed ID: 26874076
    [Abstract] [Full Text] [Related]

  • 4. A 3-week nonalcoholic steatohepatitis mouse model shows elafibranor benefits on hepatic inflammation and cell death.
    Briand F, Heymes C, Bonada L, Angles T, Charpentier J, Branchereau M, Brousseau E, Quinsat M, Fazilleau N, Burcelin R, Sulpice T.
    Clin Transl Sci; 2020 May 14; 13(3):529-538. PubMed ID: 31981449
    [Abstract] [Full Text] [Related]

  • 5. Elafibranor: a potential drug for the treatment of nonalcoholic steatohepatitis (NASH).
    Westerouen Van Meeteren MJ, Drenth JPH, Tjwa ETTL.
    Expert Opin Investig Drugs; 2020 Feb 14; 29(2):117-123. PubMed ID: 31523999
    [Abstract] [Full Text] [Related]

  • 6. Validity of biopsy-based drug effects in a diet-induced obese mouse model of biopsy-confirmed NASH.
    Baandrup Kristiansen MN, Veidal SS, Christoffersen C, Feigh M, Vrang N, Roth JD, Erickson M, Adorini L, Jelsing J.
    BMC Gastroenterol; 2019 Dec 28; 19(1):228. PubMed ID: 31883514
    [Abstract] [Full Text] [Related]

  • 7. Beneficial effects of elafibranor on NASH in E3L.CETP mice and differences between mice and men.
    van den Hoek AM, Verschuren L, Caspers MPM, Worms N, Menke AL, Princen HMG.
    Sci Rep; 2021 Mar 03; 11(1):5050. PubMed ID: 33658534
    [Abstract] [Full Text] [Related]

  • 8. Transcriptomics Reveals Discordant Lipid Metabolism Effects between In Vitro Models Exposed to Elafibranor and Liver Samples of NAFLD Patients after Bariatric Surgery.
    Boeckmans J, Gatzios A, Heymans A, Rombaut M, Rogiers V, De Kock J, Vanhaecke T, Rodrigues RM.
    Cells; 2022 Mar 04; 11(5):. PubMed ID: 35269515
    [Abstract] [Full Text] [Related]

  • 9. Elafibranor Inhibits Chronic Kidney Disease Progression in NASH Mice.
    Tsai HC, Chang FP, Li TH, Liu CW, Huang CC, Huang SF, Yang YY, Lee KC, Hsieh YC, Wang YW, Lee TY, Huang YH, Hou MC, Lin HC.
    Biomed Res Int; 2019 Mar 04; 2019():6740616. PubMed ID: 31321239
    [Abstract] [Full Text] [Related]

  • 10. Temporal Development of Dyslipidemia and Nonalcoholic Fatty Liver Disease (NAFLD) in Syrian Hamsters Fed a High-Fat, High-Fructose, High-Cholesterol Diet.
    Svop Jensen V, Fledelius C, Max Wulff E, Lykkesfeldt J, Hvid H.
    Nutrients; 2021 Feb 12; 13(2):. PubMed ID: 33673227
    [Abstract] [Full Text] [Related]

  • 11. The pharmacodynamic and differential gene expression analysis of PPAR α/δ agonist GFT505 in CDAHFD-induced NASH model.
    Liu L, Liu C, Zhao M, Zhang Q, Lu Y, Liu P, Yang H, Yang J, Chen X, Yao Y.
    PLoS One; 2020 Feb 12; 15(12):e0243911. PubMed ID: 33326461
    [Abstract] [Full Text] [Related]

  • 12. Obeticholic acid raises LDL-cholesterol and reduces HDL-cholesterol in the Diet-Induced NASH (DIN) hamster model.
    Briand F, Brousseau E, Quinsat M, Burcelin R, Sulpice T.
    Eur J Pharmacol; 2018 Jan 05; 818():449-456. PubMed ID: 29155143
    [Abstract] [Full Text] [Related]

  • 13. Combined obeticholic acid and elafibranor treatment promotes additive liver histological improvements in a diet-induced ob/ob mouse model of biopsy-confirmed NASH.
    Roth JD, Veidal SS, Fensholdt LKD, Rigbolt KTG, Papazyan R, Nielsen JC, Feigh M, Vrang N, Young M, Jelsing J, Adorini L, Hansen HH.
    Sci Rep; 2019 Jun 21; 9(1):9046. PubMed ID: 31227742
    [Abstract] [Full Text] [Related]

  • 14. Investigating fibrosis and inflammation in an ex vivo NASH murine model.
    Gore E, Bigaeva E, Oldenburger A, Jansen YJM, Schuppan D, Boersema M, Rippmann JF, Broermann A, Olinga P.
    Am J Physiol Gastrointest Liver Physiol; 2020 Feb 01; 318(2):G336-G351. PubMed ID: 31905025
    [Abstract] [Full Text] [Related]

  • 15. Elafibranor restricts lipogenic and inflammatory responses in a human skin stem cell-derived model of NASH.
    Boeckmans J, Buyl K, Natale A, Vandenbempt V, Branson S, De Boe V, Rogiers V, De Kock J, Rodrigues RM, Vanhaecke T.
    Pharmacol Res; 2019 Jun 01; 144():377-389. PubMed ID: 31028903
    [Abstract] [Full Text] [Related]

  • 16. Hepatoprotective effects of the long-acting fibroblast growth factor 21 analog PF-05231023 in the GAN diet-induced obese and biopsy-confirmed mouse model of nonalcoholic steatohepatitis.
    Nielsen MH, Gillum MP, Vrang N, Jelsing J, Hansen HH, Feigh M, Oró D.
    Am J Physiol Gastrointest Liver Physiol; 2023 May 01; 324(5):G378-G388. PubMed ID: 36852934
    [Abstract] [Full Text] [Related]

  • 17. The PPAR α/γ Agonist Saroglitazar Improves Insulin Resistance and Steatohepatitis in a Diet Induced Animal Model of Nonalcoholic Fatty Liver Disease.
    Kumar DP, Caffrey R, Marioneaux J, Santhekadur PK, Bhat M, Alonso C, Koduru SV, Philip B, Jain MR, Giri SR, Bedossa P, Sanyal AJ.
    Sci Rep; 2020 Jun 09; 10(1):9330. PubMed ID: 32518275
    [Abstract] [Full Text] [Related]

  • 18. Effects of elafibranor on liver fibrosis and gut barrier function in a mouse model of alcohol-associated liver disease.
    Koizumi A, Kaji K, Nishimura N, Asada S, Matsuda T, Tanaka M, Yorioka N, Tsuji Y, Kitagawa K, Sato S, Namisaki T, Akahane T, Yoshiji H.
    World J Gastroenterol; 2024 Jul 28; 30(28):3428-3446. PubMed ID: 39091710
    [Abstract] [Full Text] [Related]

  • 19. Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Staels B, Rubenstrunk A, Noel B, Rigou G, Delataille P, Millatt LJ, Baron M, Lucas A, Tailleux A, Hum DW, Ratziu V, Cariou B, Hanf R.
    Hepatology; 2013 Dec 28; 58(6):1941-52. PubMed ID: 23703580
    [Abstract] [Full Text] [Related]

  • 20. Inhibition of sphingosine 1-phosphate signaling ameliorates murine nonalcoholic steatohepatitis.
    Mauer AS, Hirsova P, Maiers JL, Shah VH, Malhi H.
    Am J Physiol Gastrointest Liver Physiol; 2017 Mar 01; 312(3):G300-G313. PubMed ID: 28039158
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.